Ultragenyx Pharmaceutical (RARE) Gross Profit (QoQ) (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) Gross Profit (QoQ) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -40.43%
Dec 31, 2025 34.86%
Sep 30, 2025 -8.05%
Jun 30, 2025 30.45%
Mar 31, 2025 -25.41%
Dec 31, 2024 24.48%
Sep 30, 2024 -5.78%
Jun 30, 2024 37.73%
Mar 31, 2024 -20.82%
Dec 31, 2023 32.43%
Sep 30, 2023 -11.51%
Jun 30, 2023 11.51%
Mar 31, 2023 -9.99%
Dec 31, 2022 19.44%
Sep 30, 2022 1.23%
Jun 30, 2022 9.80%
Mar 31, 2022 -7.57%
Dec 31, 2021 3.11%
Sep 30, 2021 -7.59%
Jun 30, 2021 -11.01%